Sac-TMT Meets OS End Point in Pretreated Gastroesophageal Adenocarcinoma
Merck's phase 3 TroFuse-015 trial showed sacituzumab tirumotecan improved overall survival in pretreated gastroesophageal adenocarcinoma patients, meeting its primary endpoint. The trial enrolled 473 patients, comparing the drug to treatment of physician's choice. Secondary endpoints like progression-free survival were not met, but the drug's safety profile was consistent with prior studies. Merck plans to discuss the data with regulators and present it at an upcoming medical meeting.
How this was made

The 30-second read
Why it matters
A primary OS win is a meaningful clinical milestone for Merck’s ADC pipeline, but the lack of reported hazard ratios/median OS and the failure to meet PFS by BICR reduce near-term conviction until the full dataset is shared with regulators and at a medical meeting.
Market read
Traders can reassess Merck’s oncology pipeline odds based on a Phase 3 OS primary-endpoint success, while monitoring for follow-on details (hazard ratios, median OS, and regulatory interactions).
What to watch
The release notes ORR favored sacituzumab tirumotecan but was not formally tested, and TPC included multiple chemotherapy options, which can complicate cross-trial comparisons.
Background
TroFuse-015 is a randomized, open-label Phase 3 trial of sacituzumab tirumotecan (sac-TMT) versus treatment of physician’s choice in pretreated locally advanced unresectable or metastatic gastroesophageal adenocarcinoma.
Ticker impact
Merck says TroFuse-015 Phase 3 met the primary OS endpoint for sacituzumab tirumotecan in advanced gastroesophageal adenocarcinoma versus treatment of physician’s choice.
Likely positive bias as investors price in improved probability of future filings and label expansion, tempered by missing PFS and unreported OS magnitude.
The article discloses a primary endpoint win in a global Phase 3 and notes no new safety signals, but it withholds key efficacy quantification (hazard ratios/median OS) and PFS failed by BICR.
Market effects
Reinforces the TROP2 ADC competitive set and may increase investor attention on ADCs targeting TROP2 in GI cancers, despite the PFS miss.
Primarily impacts US-listed oncology sentiment for Merck and related biotech/ADC peers, with global trial read-across.
Global Phase 3 readout can influence international regulatory discussions and future trial designs across major oncology markets.
Counterpoint
OS improvement without PFS confirmation and without disclosed hazard ratios or median OS may lead to skepticism about effect size and durability until full data are presented.
Key entities
- companyMerck
Developer with exclusive rights outside Greater China for sacituzumab tirumotecan and sponsor of TroFuse-015.
- drugsacituzumab tirumotecan
TROP2-directed antibody-drug conjugate with a belotecan-derived topoisomerase I inhibitor payload.
- clinical_trialTroFuse-015
Phase 3 trial (NCT06356311) in advanced gastroesophageal adenocarcinoma comparing sacituzumab tirumotecan to treatment of physician’s choice.



